397 related articles for article (PubMed ID: 23246812)
21. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
[TBL] [Abstract][Full Text] [Related]
22. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
[TBL] [Abstract][Full Text] [Related]
23. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
24. LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53.
Zhou X; Sang M; Liu W; Gao W; Xing E; Lü W; Xu Y; Fan X; Jing S; Shan B
Life Sci; 2012 Sep; 91(9-10):358-63. PubMed ID: 22906635
[TBL] [Abstract][Full Text] [Related]
25. p21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours.
Guillot C; Falette N; Paperin MP; Courtois S; Gentil-Perret A; Treilleux I; Ozturk M; Puisieux A
Oncogene; 1997 Jan; 14(1):45-52. PubMed ID: 9010231
[TBL] [Abstract][Full Text] [Related]
26. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Quaresima B; Faniello MC; Baudi F; Crugliano T; Di Sanzo M; Cuda G; Costanzo F; Venuta S
Oncol Rep; 2006 Oct; 16(4):811-5. PubMed ID: 16969499
[TBL] [Abstract][Full Text] [Related]
27. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.
Mirza A; McGuirk M; Hockenberry TN; Wu Q; Ashar H; Black S; Wen SF; Wang L; Kirschmeier P; Bishop WR; Nielsen LL; Pickett CB; Liu S
Oncogene; 2002 Apr; 21(17):2613-22. PubMed ID: 11965534
[TBL] [Abstract][Full Text] [Related]
28. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.
Wang Y; Xu Y; Chen J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2016 Jan; 138(2):489-96. PubMed ID: 26238069
[TBL] [Abstract][Full Text] [Related]
29. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
Elmore LW; Di X; Dumur C; Holt SE; Gewirtz DA
Clin Cancer Res; 2005 Apr; 11(7):2637-43. PubMed ID: 15814644
[TBL] [Abstract][Full Text] [Related]
30. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
31. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
Garufi A; Pistritto G; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
[TBL] [Abstract][Full Text] [Related]
32. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
33. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
Lehmann-Che J; André F; Desmedt C; Mazouni C; Giacchetti S; Turpin E; Espié M; Plassa LF; Marty M; Bertheau P; Sotiriou C; Piccart M; Symmans WF; Pusztai L; de Thé H
Oncologist; 2010; 15(3):246-52. PubMed ID: 20228131
[TBL] [Abstract][Full Text] [Related]
34. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
[TBL] [Abstract][Full Text] [Related]
35. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
36. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
37. Novel luminescent silica nanoparticles (LSN): p53 gene delivery system in breast cancer in vitro and in vivo.
Rejeeth C; Salem A
J Pharm Pharmacol; 2016 Mar; 68(3):305-15. PubMed ID: 27085860
[TBL] [Abstract][Full Text] [Related]
38. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
[TBL] [Abstract][Full Text] [Related]
39. Targeting Mdmx to treat breast cancers with wild-type p53.
Haupt S; Buckley D; Pang JM; Panimaya J; Paul PJ; Gamell C; Takano EA; Lee YY; Hiddingh S; Rogers TM; Teunisse AF; Herold MJ; Marine JC; Fox SB; Jochemsen A; Haupt Y
Cell Death Dis; 2015 Jul; 6(7):e1821. PubMed ID: 26181202
[TBL] [Abstract][Full Text] [Related]
40. Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.
Dalmases A; González I; Menendez S; Arpí O; Corominas JM; Servitja S; Tusquets I; Chamizo C; Rincón R; Espinosa L; Bigas A; Eroles P; Furriol J; Lluch A; Rovira A; Albanell J; Rojo F
Oncotarget; 2014 Jan; 5(1):196-210. PubMed ID: 24344116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
